China Pemetrexed Market Size & Outlook, 2025-2033


China Pemetrexed Market Insights

  • As highlighted in Reed Intelligence analysis, the China Pemetrexed Market, worth USD 188.13 Million in 2024, is forecasted to achieve USD 216.51 Million by 2033.
  • The China market is anticipated to grow at a CAGR of 1.6% during the period 2026–2033.
  • By 2024, Malignant Pleural Mesothelioma represented the largest share of the By Application market size.
  • Non-Squamous NSCLC is expected to remain the key growth driver within By Application, registering the fastest CAGR during the forecast period.

Other Key Findings


  • As of 2024, China held 8.04% of the global Pemetrexed Market size.
  • By 2033, United States is anticipated to capture the largest share of the global Pemetrexed Market.
  • In Asia Pacific, China is expected to lead the regional Pemetrexed Market size by 2033.
  • India will remain the fastest-growing market in Asia Pacific, reaching USD 94.95 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 188.13 Million
Market Size In 2033 USD 216.51 Million
Largest segment Malignant Pleural Mesothelioma
Units Revenue in USD Million
CAGR 1.6% (2025-2033)
Segmnetation Covered
By Application
  1. Malignant Pleural Mesothelioma
  2. Non-Squamous NSCLC
By End-User
  1. Hospitals
  2. Oncology Centers
  3. Online Pharmacies
  4. Offline Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends